Atlas Trials

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

Clinical trial NCT01300351 · COMPLETED

Trial details

NCT number
NCT01300351
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2011-03-01
Primary completion
2014-03-01
Enrollment
249

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.